ELITE PHARMACEUTICALS INC /NV/ Business Summary

Elite Pharmaceuticals Inc. (ELTP) is a specialty pharmaceutical company that generates revenue through the development, manufacture, and commercialization of niche generic and branded oral controlled-release drug products. The company’s business model is bifurcated into its Abbreviated New Drug Application (ANDA) segment, which focuses on generic pharmaceuticals, and its New Drug Application (NDA) segment for branded products. Revenue streams are primarily derived from direct sales under the proprietary "Elite Laboratories" label—launched in 2023 to capture higher margins—and licensing agreements with third-party distributors such as TAGI Pharma and Prasco. As of early 2026, the company has seen explosive growth driven by its CNS portfolio, specifically its generic versions of Vyvanse (lisdexamfetamine) and Adderall IR. Elite competes directly with specialty players like Avadel Pharmaceuticals, Amphastar Pharmaceuticals, and Aquestive Therapeutics, positioning itself as a high-efficiency manufacturer of complex dosage forms with a strategic focus on the ADHD and pain management markets. The leadership team is anchored by Chairman, CEO, and President Nasrat Hakim, who joined in 2013 and has been the primary architect of the company’s financial turnaround; Hakim brings over 30 years of industry experience from senior roles at Actavis, Watson, and Alpharma. He is supported by CFO Carter Ward, a former finance executive at Actavis and KPMG, and Chief Commercial Officer Kirko Kirkov, who joined in 2022 following leadership tenures at Vertice Pharma and Sandoz. The operational backbone is managed by EVP of Operations Doug Plassche, a Six Sigma Black Belt with a background at PAR Pharmaceuticals. Notable board members include David S. Caskey and Dr. Barry Dash, both veterans of the pharmaceutical consulting and manufacturing sectors. Nasrat Hakim remains a significant stakeholder, holding approximately 20% of the company’s outstanding shares, aligning executive incentives with long-term shareholder value.